Wegovy obesity pill set to launch in Sweden, with monthly cost expected to run into thousands of kronor
Photo: Lise Åserud/NTB/TT

Wegovy obesity pill set to launch in Sweden, with monthly cost expected to run into thousands of kronor

The obesity drug Wegovy will soon be available in tablet form in Sweden. The price has not been announced, but is expected to be similar to that of drugs already on the market - a few thousand Swedish kronor per month. “We fully understand that this can be a lot of money for an individual,” says Novo Sweden CEO Jørgen Kronborg Jungersen.

Advertisement

The tablet has already reached some pharmacies in Sweden via so-called parallel imports, as Dagens Medicin and others have reported.

According to Novo, a launch on the Swedish market is “imminent”.

The price will be made official when the launch date is announced, but it will be similar to the price of GLP-1 injections, says Jørgen Kronborg Jungersen, CEO of Novo Sweden.

The company has changed CEOs in recent years and has been forced to lay off thousands of employees, while competition from rival Eli Lilly has intensified. The latest quarterly report, however, showed stronger sales, including for the Wegovy pill.

Novo is already on the Swedish market with Ozempic and Wegovy, but both are injectable. The obvious difference from the previous preparations is that Wegovy is now available in tablet form.

It is the same active substance, he says.

No to subsidy

Ozempic is covered by the high-cost protection scheme for the treatment of type 2 diabetes. Novo has been reprimanded several times by the Swedish Dental and Pharmaceutical Benefits Agency (TLV) for providing a subsidy for Wegovy to a limited group of people with obesity.

TLV has pointed out, among other things, that more patients than intended could use the drug, leading to higher costs.

But the fight continues. In the autumn, Novo submitted a completely new application to the agency, which Kronborg Jungersen does not want to comment on further.

What would that mean for Novo?

It is not about what it would mean for Novo. It is about what it means for people living with obesity in Sweden. As things stand, you have to pay out of your own pocket if you need medical treatment.

Chronic disease

In October, the company announced that it would reduce the price of Wegovy in Sweden by 20 percent, or about 500 kronor less per month for customers.

Can Novo lower the price further?

We are doing this to keep the price at this lower level. We see that 20 percent is significant, but also something we can continue to maintain, he says.

Some people may need treatment for the rest of their lives. Since customers currently pay for it themselves, the cost is about a thousand kronor per month, depending on the dose.

It is a chronic disease, and naturally you need to take the medicine for a long time.

In this story
AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All